Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 3, 2011, Pages 952-963

  Di Cresce, C ^a,b   Figueredo, R ^a,b   Ferguson, P J ^a,b   Vincent, M D ^a,b   Koropatnick, James ^a,b  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLOXURIDINE; MESSENGER RNA; PEMETREXED; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA; THYMIDINE KINASE 1; THYMIDINE KINASE 2; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIZATION; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; UPREGULATION;

ACTINS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; FLOXURIDINE; GLUTAMATES; GUANINE; HELA CELLS; HUMANS; RNA, SMALL INTERFERING; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TRANSFECTION;

EID: 80052172641     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.183178     Document Type: Article

References (40)

1. Aigner A (2007) Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 76:9-21.
2. Anderson EM, Birmingham A, Baskerville S, Reynolds A, Maksimova E, Leake D, Fedorov Y, Karpilow J, and Khvorova A (2008) Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 14:853-861. (Pubitemid 351574907)
3. Arnér ES and Eriksson S (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67:155-186.
4. Behlke MA (2006) Progress towards in vivo use of siRNAs. Mol Ther 13:644-670.
5. Berg RW, Ferguso PJ, DeMoor JM, Vincen MD, and Koropatnick J (2002) The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger. Curr Drug Targets 3:297-309. (Pubitemid 34705093)
6. 2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase. J Pharmacol Exp Ther 298:477-484.
7. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, et al. (2006) 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3:199-204.
8. Buzaid AC, Alberts DS, Einspahr J, Mosley K, Peng YM, Tutsch K, Spears CP, and Garewal HS (1989) Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients. Cancer Chemother Pharmacol 25:124-130. (Pubitemid 20009440)
9. Carreras CW and Santi DV (1995) The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64:721-762.
10. Castanotto D and Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-433.
11. Castanotto D, Sakurai K, Lingeman R, Li H, Shively L, Aagaard L, Soifer H, Gatignol A, Riggs A, and Rossi JJ (2007) Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res 35:5154-5164. (Pubitemid 47394199)
12. Chattopadhyay S, Moran RG, and Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404-417. (Pubitemid 46332443)
13. Chen PY, Weinmann L, Gaidatzis D, Pei Y, Zavolan M, Tuschl T, and Meister G (2008) Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 14:263-274. (Pubitemid 351171587)
14. Chu E, Callender MA, Farrell MP, and Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52(Suppl 1):S80-S89. (Pubitemid 37047028)
15. Costi MP (1998) Thymidylate synthase inhibition: a structure-based rationale for drug design. Med Res Rev 18:21-42.
16. Derenzini M, Montanaro L, Treré D, Chillà A, Tazzari PL, Dall'Olio F, and Ofner D (2002) Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines. Mol Pathol 55:310-314. (Pubitemid 35193258)
17. Di Cresce C and Koropatnick J (2010) Antisense treatment in human prostate cancer and melanoma. Curr Cancer Drug Targets 10:555-565.
18. Douglas KT (1987) The thymidylate synthesis cycle and anticancer drugs. Med Res Rev 7:441-475.
19. Ferguson PJ, Collins O, Dean NM, DeMoor J, Li CS, Vincent MD, and Koropatnick J (1999) Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol 127:1777-1786.
20. Ferguson PJ, DeMoor JM, Vincent MD, and Koropatnick J (2001) Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells. Br J Pharmacol 134:1437-1446.
21. Flynn J, Berg RW, Wong T, van Aken M, Vincent MD, Fukushima M, and Koropatnick J (2006) Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol Cancer Ther 5:1423-1433. (Pubitemid 44070478)
22. Fujiwaki R, Hata K, Nakayama K, Moriyama M, Iwanari O, Katabuchi H, Okamura H, Sakai E, and Miyazaki K (2002) Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes. Int J Cancer 99:328-335. (Pubitemid 34495846)
23. Hamblin TJ (2007) Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 20:455-468.
24. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, and Scheiner J (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663-666.
25. Hu CM and Chang ZF (2007) Mitotic control of dTTP pool: a necessity or coincidence? J Biomed Sci 14:491-497.
26. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12:1197-1205. (Pubitemid 43990545)
27. Kanwar JR, Kamalapuram SK, and Kanwar RK (2010) Targeting survivin in cancer: patent review. Expert Opin Ther Pat 20:1723-1737.
28. Khvorova A, Reynolds A, and Jayasena SD (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell 115:209-216. (Pubitemid 37329584)
29. Kinsella AR, Smith D, and Pickard M (1997) Resistance to chemotherapeutic anti-metabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 75:935-945. (Pubitemid 27122610)
30. Kitchens ME, Forsthoefel AM, Rafique Z, Spencer HT, and Berger FG (1999) Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation. J Biol Chem 274:12544-12547.
31. Lares MR, Rossi JJ, and Ouellet DL (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28:570-579.
32. 18F]fluorothymidine flare. Biochem Pharmacol 80:1528-1536.
33. Longley DB, Harkin DP, and Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338. (Pubitemid 37328853)
34. Luo P, Wang N, He E, Eriksson S, Zhou J, Hu G, Zhang J, and Skog S (2010) The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells. Pathol Oncol Res 16:277-283.
35. Nagarajan M and Johnson LF (1989) Regulation of thymidylate synthase gene expression in mouse fibroblasts synchronized by mitotic selection. Exp Cell Res 181:289-297. (Pubitemid 19072812)
36. Pandyra AA, Berg R, Vincent M, and Koropatnick J (2007) Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines. J Pharmacol Exp Ther 322:123-132. (Pubitemid 46956354)
37. Pérez-Pérez MJ, Priego EM, Hernández AI, Familiar O, Camarasa MJ, Negri A, Gago F, and Balzarini J (2008) Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future. Med Res Rev 28:797-820.
38. Pickard M and Kinsella A (1996) Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites. Biochem Pharmacol 52:425-431. (Pubitemid 26233585)
39. Schmitz JC, Liu J, Lin X, Chen TM, Yan W, Tai N, Gollerkeri A, and Chu E (2001) Translational regulation as a novel mechanism for the development of cellular drug resistance. Cancer Metastasis Rev 20:33-41. (Pubitemid 34074676)
40. Svobodova S, Topolcan O, Holubec L, Treska V, Sutnar A, Rupert K, Kormunda S, Rousarova M, and Finek J (2007) Prognostic importance of thymidine kinase in colorectal and breast cancer. Anticancer Res 27:1907-1909. (Pubitemid 46954696)